Module
Hepatitis C Treatment: 2005
Source: Hepatitis Annual Update 2005
Hepatitis C Treatment: 2005
Program Director: Patrick J. Lynch, MD
|
Learning Objectives
Upon completion of this activity, participants should be able to:
Recognize challenges in the treatment of hepatitis C in select populations, including African-Americans, patients with renal failure or on dialysis, patients coinfected with HIV-1, those with acute hepatitis C, and nonresponders. Understand the status of new drugs in development for treatment of hepatitis C, including nucleosides and viramidine. Discuss new developments in the treatment of hepatitis C.
Content includes:
- Currently Available Treatments: Peginterferon and Ribavirin
- New Drugs in Development: Viramidine
- Other New Drugs in Development
- Challenges in the Treatment of Hepatitis C: African-Americans
- Patients With Renal Failure or Receiving Dialysis
- Patients Coinfected With HIV-1
- Acute Hepatitis C
- Nonresponders
|
Disclaimer:
The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Northwestern University’s Feinberg School of Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|
|